GlassScriptPhysician profile
Martha Valdivia
NPI 1083646970
$8,570.75
in general payments reported to CMS, 2019-2025
42 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $649 · 2021: $1,581 · 2022: $1,482 · 2023: $1,444 · 2024: $1,269 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,928 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,928.16 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $987.21 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $944.75 | 2019-2025 | Linzess, Viberzi, Creon |
| Glaxosmithkline, LLC. | $735.03 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $548.27 | 2020-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $475.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $422.23 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $393.32 | 2022-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $354.70 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $349.22 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $338.15 | 2019-2021 | |
| Lilly USA, LLC | $267.79 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.73 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $243.33 | 2020-2024 | Linzess |
| Astrazeneca Pharmaceuticals LP | $241.74 | 2019-2025 | Lokelma, Airsupra, Farxiga |
| Ardelyx, INC. | $216.01 | 2024-2025 | Ibsrela |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Valdivia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.